Protocol Ledger

NCT07301034 · Phase III · RECRUITING

A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack

Interventional Phase III clinical trial protocol NCT07301034 sponsored by Novo Nordisk in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-12-18 Enrollment: 332 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07301034
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)332 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07301034
Protocol FieldVerified Registry Value
NCT IdentifierNCT07301034
Consolidated Lead SponsorNovo Nordisk
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment332 participants (ESTIMATED)
Registered Start Date2025-12-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07301034
Hospital Research SiteLocationSite Profile
Medizinische Universität WienVienna, AustriaOpen Hospital Dossier ->
RadboudumcNijmegen, NetherlandsOpen Hospital Dossier ->
Erasmus MCRotterdam, NetherlandsOpen Hospital Dossier ->
Hospital Universitario de La PrincesaMadrid, SpainOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novo Nordisk across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI